2024年ASCO年会HR+/HER2-晚期乳腺癌治疗研究进展  

Research progress on the treatment of HR+/HER2-metastatic breast cancer at 2024 American Society of Clinical Oncology annual meeting

作　　者：方梓儒 周欢欢(综述) 王晓稼(审校)[2] Ziru Fang;Huanhuan Zhou;Xiaojia Wang(Zhejiang Chinese Medical University,Hangzhou 310053,China;Zhejiang Cancer Hospital,Hangzhou 310022,China)

机构地区：[1]浙江中医药大学,杭州市310053 [2]浙江省肿瘤医院

出　　处：《中国肿瘤临床》2024年第22期1164-1169,共6页Chinese Journal of Clinical Oncology

基　　金：国家重点研发计划“政府间国际科技创新合作/港澳台科技创新合作”重点专项立项项目(编号:2019YFE0196500);2020年度浙江省重点研发计划项目(国际合作技术研发与示范推广项目)(编号:2020C04012)资助。

摘　　要：2024年美国临床肿瘤学会(American Society of Clinical Oncology,ASCO)年会的主题为“癌症诊疗的科学与艺术:从关怀到治愈(The art and science of cancer care:from comfort to cure)”。在晚期乳腺癌领域,激素受体(hormonal receptor,HR)阳性/人类表皮生长因子受体-2(human epidermal growth factor receptor 2,HER2)阴性亚型的相关研究占据大量篇幅,其中3篇压轴公布的重要研究(late-breaking abstract,LBA)分别报道了post MONARCH研究(LBA1001)、Young-PEARL研究(LBA1002)、SACI-IO HR+研究(LBA1004)的最新结果,引起广泛关注。本文就本次年会中关于HR+/HER2-晚期乳腺癌治疗的研究进展进行综合报道。The theme of the 2024 American Society of Clinical Oncology(ASCO)Annual Meeting is"The art and science of cancer care:from comfort to cure."Extensive research was presented on the hormonal receptor(HR)-positive/human epidermal growth factor receptor 2(HER2)-negative subtype of metastatic breast cancer.Three late-breaking abstracts(LBA)reported the latest findings of the post MONARCH(LBA1001),Young-PEARL(LBA1002),and SACI-IO HR+(LBA1004)studies,generating significant interest.In this paper,we present a comprehensive review of the progress on HR+/HER2-metastatic breast cancer treatment research as reported at this annual meeting.

关 键 词：乳腺癌 雌激素受体 激素受体 CDK4/6抑制剂 抗体药物偶联物 

分 类 号：R737.9[医药卫生—肿瘤]